Strong international growth in Trauma/LOQTEQ® product sales in H1 2013

aap Implantate AG / Strong international growth in Trauma/LOQTEQ® product sales in H1 2013 . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

aap Implantate AG (XETRA: AAQ.DE) reports, on the basis of preliminary figures, sales growth to EUR 19.5 million (previous year: EUR 18.9 million) in the first half of the financial year 2013. Second quarter sales rose by 2% to EUR 9.2 million. Temporarily lower OEM sales of bone cements could be compensated by strong growth of LOQTEQ® sales and in its slipstream the sales of the other Trauma portfolio showed attractive growth.

Total Trauma/LOQTEQ® Sales increased during the first half of 2013 by 75% to EUR 4.2 million, compared with EUR 2.4 million in the first half of 2012. During the second quarter among other events a new Russian customer for the Total Trauma portfolio was appointed as distributor with immediate supply. This achievement represents another step in realizing the goal to appoint next to distributors in the USA and EU also distributors in at least 7 of the 9 BRICS and MIST countries before year end (now 5).

The figures for both financial years include revenue from the conclusion of license and supply agreements, a license agreement that was signed in March 2012 having exerted a material influence (+EUR 2.2 million) on the sales total. The two development and supply agreements signed in March 2013 have a combined sales effect of EUR 3.1 million. We anticipate EBITDA growth of around 17% in the first half of 2013. Second quarter EBITDA was lower than in the previous year as already reported because Biomaterials sales were down slightly.

  

	2013  (in EUR million)	2012  (in EUR million)	Change on year
Sales
Q1	10.4	9.9	5%
Q2e*	9.2	9.0	2%
H1e*	19.5	18.9	3%
EBITDA
Q1	3.1	2.1	48%
Q2e*	1.0	1.4	-29%
H1e*	4.1	3.5	17%

                               * Estimated figure for the period in question in 2013

As a result of the ongoing implementation of our focus strategy on Trauma and Biomaterials the company announced by the end of the second quarter the closing of joint venture agreement for the non core Recon portfolio for a consideration of EUR 3 million in cash. In this joint venture aap is the junior partner with 33% of the shares.

aap Implantate AG will update its guidance for the third quarter and the full year 2013 to include the impact of the joint venture in conjunction with the publication of the report for the second quarter on August 14, 2013.